LYTIR

Company · PVLA

Palvella Therapeutics, Inc.

Name as listed on its exchange; filed with the SEC as PALVELLA THERAPEUTICS, INC.

Nasdaq's symbol directory lists PVLA on Nasdaq as “Palvella Therapeutics, Inc. - Common Stock”.

In the 12 months to Nov 19, 2026: insiders sold on 14 occasions ($12.8M); 5 planned-sale notices; 7 filings by holders of 5% or more; 2 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC · Appeared in No. 22

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $12.8M in total.Jun: Insider sales $476KJul: Insider sales $642KAug: Insider sales $655KSep: Insider sales $4.9MOct: Insider sales $4.1MNov: Insider sales $2.1MDecJanFebMarAprMayJunJulAugSepOctNov$4.9M
Insider purchases above the line: $0Insider sales below: $12.8M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. JENKINS GEORGE M sold on 6 days all under a 10b5-1 plan latest Oct 14, 2026 sold $7.7M
  2. Goin Kathleen, Chief Operating Officer sold on 5 days all under a 10b5-1 plan latest Oct 21, 2026 sold $3.0M
  3. Martini Jeffrey S, Chief Scientific Officer sold on 2 days all under a 10b5-1 plan latest Nov 11, 2026 sold $2.1M
  4. KIRITSY CHRISTOPHER P sold on 1 day latest Sep 2, 2026 sold $49K
Every trade (14)
  1. SELLMartini Jeffrey S, Chief Scientific Officer sold Nov 11, 2026 6,250 shares 6 legs combined 10b5-1 plan (scheduled) filing $1.0M
  2. SELLMartini Jeffrey S, Chief Scientific Officer sold Nov 10, 2026 6,250 shares 7 legs combined 10b5-1 plan (scheduled) filing $1.0M
  3. SELLGoin Kathleen, Chief Operating Officer sold Oct 21, 2026 4,313 shares 3 legs combined 10b5-1 plan (scheduled) filing $537K
  4. SELLJENKINS GEORGE M sold Oct 14, 2026 7,174 shares 6 legs combined 10b5-1 plan (scheduled) filing $886K
  5. SELLJENKINS GEORGE M sold Oct 13, 2026 7,174 shares 6 legs combined 10b5-1 plan (scheduled) filing $935K
  6. SELLJENKINS GEORGE M sold Oct 12, 2026 13,152 shares 5 legs combined 10b5-1 plan (scheduled) filing $1.8M
  7. SELLGoin Kathleen, Chief Operating Officer sold Sep 16, 2026 4,302 shares 3 legs combined 10b5-1 plan (scheduled) filing $655K
  8. SELLJENKINS GEORGE M sold Sep 15, 2026 1,777 shares 3 legs combined 10b5-1 plan (scheduled) filing $267K
  9. SELLJENKINS GEORGE M sold Sep 14, 2026 13,352 shares 3 legs combined 10b5-1 plan (scheduled) filing $2.0M
  10. SELLJENKINS GEORGE M sold Sep 11, 2026 12,371 shares 3 legs combined 10b5-1 plan (scheduled) filing $1.9M
  11. SELLKIRITSY CHRISTOPHER P sold Sep 2, 2026 313 shares filing $49K
  12. SELLGoin Kathleen, Chief Operating Officer sold Aug 19, 2026 4,302 shares 5 legs combined 10b5-1 plan (scheduled) filing $655K
  13. SELLGoin Kathleen, Chief Operating Officer sold Jul 15, 2026 4,302 shares 4 legs combined 10b5-1 plan (scheduled) filing $642K
  14. SELLGoin Kathleen, Chief Operating Officer sold Jun 17, 2026 4,302 shares 3 legs combined 10b5-1 plan (scheduled) filing $476K

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. JEFFREY MARTINI filed Nov 10, 2026 Officer 50,000 shares planned sale date 11/10/2026 filing $8.7M
  2. Goin Kathleen filed Oct 21, 2026 Officer 4,313 shares planned sale date 10/21/2026 filing $534K
  3. JENKINS GEORGE M filed Oct 13, 2026 Director 27,500 shares planned sale date 10/13/2026 filing $3.7M
  4. Goin Kathleen filed Sep 16, 2026 Officer 4,302 shares planned sale date 09/16/2026 filing $651K
  5. JENKINS GEORGE M filed Sep 11, 2026 Director 27,500 shares planned sale date 09/11/2026 filing $4.1M

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Frazier Life Sciences Public Fund, L.P. filed Nov 16, 2026 Schedule 13G/A passive filing 5.9%
  2. Jennison Associates LLC filed Oct 28, 2026 Schedule 13G/A passive 1,101,652 shares filing 7.7%
  3. First Light Asset Management, LLC filed Aug 14, 2026 Schedule 13G/A passive filing 5.34%
  4. BIOTECHNOLOGY VALUE FUND L P filed Aug 14, 2026 Schedule 13G/A passive filing 4.7%
  5. PRUDENTIAL FINANCIAL INC filed Aug 10, 2026 Schedule 13G passive 962,374 shares filing 6.7%
  6. Jennison Associates LLC filed Aug 3, 2026 Schedule 13G passive 960,619 shares filing 6.7%
  7. BlackRock, Inc. filed Jul 29, 2026 Schedule 13G passive 812,953 shares filing 5.7%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition; Regulation FD disclosure filing Nov 5, 2026
  2. Other events filing Oct 28, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.